Multi-center, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study of Conbercept Ophthalmic Injection for Patients With BRVO
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Conbercept (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Acronyms BRAVE
- Sponsors Chengdu Kanghong Biotech
- 19 Sep 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2020.
- 19 Sep 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2019.
- 13 Apr 2017 New trial record